NCH Healthcare System [ ICU] Antibiogram 2012 data collection period Oct 2010 - Sept 2011(% Susceptible)

organism avg.

# tes

ted

amika

cinam

picil

linam

p/su

lbce

fazo

lince

fepi

me

cefo

xitin

cefta

zidim

ece

ftriax

one

cipro

floxa

ciner

tape

nem

gent

amici

nim

ipen

emlev

oflo

xacin

nitro

fura

ntio

npi

p/ta

zotig

ecyc

line

tobr

amyc

intri

met

h/su

lfa

E.coli 55 96 36.3 54.5 78.1 87.2 85.1 87.2 87.2 47.2 100 87.2 100 49 94.2 100 78.1 68.5

K.pneumoniae 36 1 80.7 75 83.3 83.3 88.8 83.3 83.3 86.1 94.1 94.4 88.8 86.1 78 87.5 86.1 80.5

Ps.aeruginosa 41 1 95.1 87.8 80.4 80.9 78.5 92.8 66.6 92.3 95.2

organism avg.

# tes

ted

ampi

cillin

cipro

floxa

cincli

ndam

ycin

dapt

omyc

iner

ythr

omyc

inge

ntam

icin

gent

amici

n sy

nerg

ystr

epto

myc

in sy

nerg

y

levof

loxa

cinlin

ezol

idm

oxifl

oxcin

nitro

fura

ntio

nox

acilli

nrif

ampi

nte

tracy

cline

tigec

yclin

etri

met

h/su

lfava

ncom

ycin

S.aureus 63 38 41.2 100 23.8 95.2 95.2 38 100 49.2 49.2 36.5 96.8 100 100 100 100 Enterococcus spp. <30 1 83.3 61 100 17.6 95.4 65 65.5 91 95 14 100 90

1results should be interpreted with caution since the number of isolates does not meet the statistically valid number of >50 isolates, recommended by CLSI 2 Enterococcus spp. includes: E. faecium, E.faecalis and two VRE's Vancomycin Resistant Enterococci

Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.

NCH Healthcare System ED Antibiogram 2012

Common Gram-Positive Bacterial Pathogens (% - Susceptible) Data Collected Oct 2010 – Sept 2011

Pathogens

Avg. #

Tested

A m p i c i l l i n

C e f t r i a x o n e

C l i n d a m y c i n

C i p r o f l o x a c I n

D a p t o m y c i n

E r y t h r o m y c i n

G e n t a m i c i n

G e n t a m i c i n

S y n e r g y

L e v o f l o x a c i n

L i n e z o l i d

N i t r o f u r a n t o i n

O x a c i l l i n

P e n i c i l l i n

R i f a m p i n

T e t r a c y c l i n e

T i g e c y c l i n e

T r i

m e t h / S u l f a

V a n c o m y c i n

Enterococcus spp 136 99 80 83 82 100 99 18 100 100 Staph aureus 55 70 64 100 57 100 64 100 95 64 97 88 100 100 100 Strep pneumoniae * 29 99 59 100 68 76 100 Antibiotics which are not reported are either inactive against the organism, or the resistance rate is > 50%, or not a drug of choice. # Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI.

• Gentamicin may provide synergistic activity when used in combination therapy with a penicillin (ampicillin) or vancomycin for deep-seeded enterococcal infections. • Rifampin should not be used as a single agent for treatment but may be effectively used as combination therapy with vancomycin, trimethoprim/sulfamethoxazole, or doxycycline or minocycle • Strep pneumoniae: Includes Data from ED patients and Inpatient sterile sites (Blood, CSF, Fluid, Lung Tissue)

Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.

NCH Healthcare System ED Urine Antibiogram 2012 Common Gram-Negative Bacterial Pathogens (% - Susceptible)

Data Collected Oct 2010 – Sept 2011

Pathogens

Avg. # Tested

A m i k a c i n

A m p / S u l b a c t a m

A m p i c i l l i n

C e f a z o l i n

C e f e p i m e

C e f o x i t i n

C e f t a z i d i

m e

C e f t r i a x o n e

C i p r o f l o x a c i n

E r t a p e n e m

G e n t a m i c i n

I m i p e n e m

L e v o f l o x a c i n

N i t r o f u r a n t o i n

P i p / T a z o b a c t a m

T o b r a m y c i n

T r i m e t h / S u l f a

Citrobacter freundii

*21 100 100 0 100 100 100 100 100 100 100 100 100 100 86

Enterobacter aerogenes

*29 100 100 96 96 90 100 100 100 90 14 96 100 100

Enterobacter cloacae

* 17 100 100 76 76 100 100 100 100 100 33 93 100 88

Escherichia coli 1506 100 68 53 87 96 93 95 95 81 100 92 100 81 95 95 91 73

ESBL Escherichia coli

67 100 13 12 100 73 100 12 92 50 53 59

Klebsiella pneumoniae

245 100 93 96 98 98 98 98 97 100 99 100 97 26 99 98 90

Proteus mirabilis

145 100 92 76 94 100 99 100 100 92 100 94 92 98 97 96

Pseudomonas aeruginosa

59 98 88 95 77 82 93 71 96 97

Serratia marcescens

* 23 100 100 23 100 96 91 100 100 100 91 91 100 100

Stenotrophomonas maltophilia

* 30 90

■ Antibiotics which are not reported are either inactive against the organism, or , the resistance rate is > 50%, or, not a drug of choice. * Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI. Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.

NCH Healthcare System Inpatient Antibiogram 2012 Common Gram-Negative Bacterial Pathogens (% - Susceptible)

Inpatient Data Collected Oct 2010 – Sept 2011

Pathogens

Avg. # Tested

A m i k a c i n

A m p / S u l b a c t a m

A m p i c i l l i n

C e f a z o l i n

C e f e p i m e

C e f o x i t i n

C e f t a z i d i

m e

C e f t r i a x o n e

C i p r o f l o x a c i n

E r t a p e n e m

G e n t a m i c i n

I m i p e n e m

L e v o f l o x a c i n

N i t r o f u r a n t o i n

P i p / T a z o b a c t a m

T o b r a m y c i n

T r i m e t h / S u l f a

Citrobacter freundii

33 100 100 0 82 85 79 100 89 100 79 87 86 94 79

Enterobacter aerogenes

47 100 100 91 91 96 100 98 100 94 7 84 100 98

Enterobacter cloacae

74 98 97 81 82 85 98 89 100 85 33 80 90 88

Escherichia coli 1415 100 60 47 82 90 88 89 90 64 100 89 100 64 94 94 86 71

ESBL Escherichia coli

138 97 4 3 100 73 100 3 89 77 43 54

Klebsiella pneumoniae

433 99 83 91 93 93 93 93 92 100 98 99 93 96 96 91

Proteus mirabilis

204 99 93 74 89 95 94 95 95 76 100 93 77 98 95 78

Pseudomonas aeruginosa

363 97 85 93 77 87 93 71 89 97

Serratia marcescens

* 23 100 100 23 100 96 91 100 100 100 91 91 100 100

Stenotrophomonas maltophilia

* 30 90

■ Antibiotics which are not reported are either inactive against the organism, or , the resistance rate is > 50%, or, not a drug of choice. * Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI. Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.

NCH Healthcare System Inpatient Antibiogram 2012

Common Gram-Positive Bacterial Pathogens (% - Susceptible) Inpatient Data Collected Oct 2010 – Sept 2011

Pathogens

Avg. #

Tested

A m p i c i l l i n

C e f t r i a x o n e

C l i n d a m y c i n

C i p r o f l o x a c I n

D a p t o m y c i n

E r y t h r o m y c i n

G e n t a m i c i n

G e n t a m i c i n

S y n e r g y

L e v o f l o x a c i n

L i n e z o l i d

N i t r o f u r a n t o i n

O x a c i l l i n

P e n i c i l l i n

R i f a m p i n

T e t r a c y c l i n e

T i g e c y c l i n e

T r i

m e t h / S u l f a

V a n c o m y c i n

Enterococcus faecium 41 100 10 100 24 100 17 Enterococcus spp 230 96 79 100 76 72 99 94 17 100 100 Staph aureus 688 56 45 100 58 83 45 100 99 45 97 94 100 98 100 Staph epidermidis 159 55 30 32 69 30 100 99 26 95 84 100 100 Strep pneumoniae * 29 99 59 100 68 76 100 Antibiotics which are not reported are either inactive against the organism, or the resistance rate is > 50%, or not a drug of choice. # Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI.

• Gentamicin may provide synergistic activity when used in combination therapy with a penicillin (ampicillin) or vancomycin for deep-seeded enterococcal infections. • Rifampin should not be used as a single agent for treatment but may be effectively used as combination therapy with vancomycin, trimethoprim/sulfamethoxazole, or doxycycline or minocycle • Strep pneumoniae: Includes Data from ED patients and Inpatient sterile sites (Blood, CSF, Fluid, Lung Tissue)

Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.